William Blair Comments on DexCom's Q2 Earnings (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM - Free Report) - Stock analysts at William Blair reduced their Q2 2025 earnings per share estimates for DexCom in a research report issued on Monday, May 5th. William Blair analyst M. Andrew now anticipates that the medical device company will post earnings per share of $0.46 for the quarter, down from their previous estimate of $0.47. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom's Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.04 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.53 EPS.

DXCM has been the subject of a number of other reports. Robert W. Baird dropped their price target on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday. Cfra Research raised DexCom to a "hold" rating in a research note on Friday, March 21st. Citigroup increased their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Barclays increased their target price on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average price target of $98.11.

DexCom Stock Down 1.7 %

NASDAQ DXCM opened at $80.27 on Tuesday. DexCom has a 52 week low of $57.52 and a 52 week high of $132.26. The firm has a market capitalization of $31.47 billion, a price-to-earnings ratio of 56.13, a PEG ratio of 2.30 and a beta of 1.43. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average of $71.27 and a two-hundred day moving average of $76.93.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter last year, the firm posted $0.32 EPS. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year.

Insider Transactions at DexCom

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. This represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 66,926 shares of company stock valued at $4,734,384. Corporate insiders own 0.32% of the company's stock.

Institutional Investors Weigh In On DexCom

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of DexCom during the fourth quarter valued at about $385,367,000. Jennison Associates LLC grew its position in DexCom by 37.7% during the 1st quarter. Jennison Associates LLC now owns 10,523,246 shares of the medical device company's stock worth $718,632,000 after purchasing an additional 2,879,489 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in DexCom by 171.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 3,194,829 shares of the medical device company's stock valued at $218,175,000 after purchasing an additional 2,015,971 shares in the last quarter. Congress Asset Management Co. raised its holdings in shares of DexCom by 5,456.9% in the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after buying an additional 1,332,522 shares during the last quarter. Finally, Fisher Funds Management LTD purchased a new position in shares of DexCom in the fourth quarter worth $96,507,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.